Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S297000, C544S405000
Reexamination Certificate
active
10840485
ABSTRACT:
The present invention relates to compounds of Formula I,or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF1receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF1receptors.
REFERENCES:
patent: 5872136 (1999-02-01), Anthony et al.
patent: 5880140 (1999-03-01), Anthony
patent: 5883105 (1999-03-01), Anthony
patent: 6043260 (2000-03-01), Chen et al.
patent: 6964965 (2005-11-01), Corbett et al.
patent: 1097709 (2000-10-01), None
patent: 9735901 (1997-10-01), None
patent: 9736886 (1997-10-01), None
patent: 9736898 (1997-10-01), None
patent: 9829119 (1998-07-01), None
patent: 0160806 (2001-08-01), None
patent: 00160806 (2001-08-01), None
patent: 03045924 (2003-06-01), None
patent: 03091225 (2003-11-01), None
patent: 04024719 (2004-03-01), None
Kehne and De Lombert, “Non-Peptidic CRF1 Receptor Antagonists for the Treatment of Anxiety, Depression and Stress Disorders” Current Drug Targets, vol. 1(5), pp. 467-493 (2002).
Dautzenberg and Hauger, “The CRF peptide family and their receptors: yet more partners discovered” Trends in Pharmacological Sciences, vol. 23(2), pp. 71-77 (Feb. 2002).
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Corbett Jeffrey W.
Ennis Michael Dalton
Frank Kristine E.
Fu Jian-Min
Hoffman Robert Louis
Ebel Eileen M.
Pfizer Inc
Tucker Zachary C
Zelson Steve T.
LandOfFree
Compounds as CRF 1 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as CRF 1 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as CRF 1 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776870